Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04851964 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
A Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
- 20
- Study locations
NCT04851964: Completed Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca.
NCT04851964 is a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps that has completed, run by AstraZeneca. The registered enrollment target is 416 participants, above the 105-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (296% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04851964, a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
Primary Outcome
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Experimental: Tezepelumab
- DRUG Mometasone furoate or equivalent intranasal corticosteroid
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Newport Beach
- Research Site - Roseville
- Research Site - Walnut Creek
Colorado
- Research Site - Colorado Springs
- Research Site - Denver
Maryland
- Research Site - Baltimore
- Research Site - White Marsh
Alabama
- Research Site - Birmingham
Florida
- Research Site - Boca Raton
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Boston
Missouri
- Research Site - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 3 |
What the finished NCT04851964 record still lists
NCT04851964 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, above the 105-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (296% higher).
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04851964 names 20 study sites across 15 states, led by California, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT04851964 about?
NCT04851964 is a clinical study titled "Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis". A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
What is the current status of trial NCT04851964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2021-04-22. Estimated completion is 2024-12-11.
What conditions does trial NCT04851964 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.
What interventions are being tested in trial NCT04851964?
The interventions under investigation include: Placebo (OTHER), Experimental: Tezepelumab (BIOLOGICAL), Mometasone furoate or equivalent intranasal corticosteroid (DRUG).
Who is sponsoring clinical trial NCT04851964?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04851964 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis With Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04851964's enrollment target sits among peer trials
416 1st of 11 higher than 11 of 11 other Chronic Rhinosinusitis With Nasal Polyps trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Rhinosinusitis With Nasal Polyps trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
RECRUITING · Phase 3
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
RECRUITING · Phase 2
-
The Role of IL5 in Epithelial Cell Integrity
RECRUITING · Early Phase 1
-
3D Printing to Improve Nasal Irrigation Outcome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- NCT06075745 · 416 participants · Phase 2
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI